Cassava Sciences Inc vs HubSpot Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while HubSpot Inc trades at $211.66 (market cap $11.00B). The key difference: HubSpot Inc is far larger — about 230.4× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | HUBS | |
|---|---|---|
Market Cap | $47.75M | $11.00B |
Sector | Health | Technology |
52-Week High | $4.64 | $522.97 |
52-Week Low | $0.87 | $170.39 |
Enterprise Value | -$34.93M | $9.89B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
HubSpot (HUBS) trades at $215.91, up 2.64% today but remains in a bearish technical trend. The company reported strong Q2 2026 earnings with EPS of $3.26 beating estimates, but lowered customer growth guidance to 5,000-6,000 per quarter. Revenue grew 20% year-over-year to $3.13 billion in 2025, with net income improving to $45.91 million. However, the stock faces headwinds from AI transition costs and a securities fraud investigation announced on August 10, 2026.
Despite near-term challenges, HubSpot maintains strong fundamentals with 76.6% analyst buy ratings and a $233.93 consensus target. The AI pivot creates execution risk but offers long-term growth potential. Key risks include customer acquisition slowdown, competitive pressures, and legal uncertainties. Current valuation at 78.5x P/E requires sustained execution for further upside.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →